Table 1.
Description of the cohorts
| Variables | Cohort 1 N = 13 | Cohort 2 N = 74 |
|---|---|---|
| Agea (years) | 48.3 ± 9.3 | 51.9 ± 8.5 |
| BMIa (kg/m2) | 28.2 ± 6.8 | 26.2 ± 5.6 |
| Menopausal statusb | ||
| Premenopause | 8 (61.54) | 17 (22.97) |
| Postmenopause | 5 (38.46) | 57 (77.03) |
| ER statusb | ||
| Positive | 8 (61.54) | 69 (93.24) |
| Negative | 5 (38.46) | 5 (6.76) |
| PR statusb | ||
| Positive | 7 (53.85) | 65 (87.84) |
| Negative | 6 (46.15) | 9 (12.16) |
| HER2 statusb | ||
| Positive | 4 (30.77) | 8 (10.81) |
| Negative | 5 (38.46) | 54 (72.97) |
| Not assessable | 4 (30.77) | 12 (16.22) |
| BCb | ||
| DCIS | 4 (30.77) | 5 (6.76) |
| IDC | ||
| Luminal | 4 (30.77) | 65 (87.84) |
| HER2+ | 2 (15.38) | 1 (1.35) |
| Triple negative | 3 (23.08) | 1 (1.35) |
| Unclassified | – | 2 (2.70) |
BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, BC breast cancer, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma
Data presented as amean ± SD, bnumber of individuals (%)